Uncategorized

La inteligencia artificial (IA) está emergiendo como una herramienta clave en la lucha por conservar nuestros océanos. En un contexto de cambio climático, sobrepesca, contaminación y pérdida de biodiversidad marina, los científicos están recurriendo a …

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts parsing the data presented at the American Diabetes Association annual meeting this week.

Anticipating rising demand for ophthalmic surgery but a shortage of surgeons, the Israel-based company said it is developing the world’s first robotic surgery platform for cataracts and other eye diseases.

Co-founder Christopher McGhee reacquired the company nearly four years after the electronics retailer purchased the home care business.

A federal judge ruled in favor of a whistleblower, finding CVS’ pharmacy benefit manager Caremark overbilled Medicare for generic drugs.

Store closures and weak front-of-store sales led to a retail sales decline in Q3, but U.S. pharmacy and international sales were strong.

The health system blamed the layoffs on regulatory uncertainty and rising costs of providing care.

J&J is offering up to $100,000 in grant funding, mentorship and access to computing capabilities.

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic mitochondria.

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.